PL2501384T5 - Sposób leczenia zaburzeń proliferacyjnych i innych stanów patologicznych, w których pośredniczy aktywność kinazowa BCR-AbI, c-Kit, DDR1, DDR2 lub PDGF-R - Google Patents

Sposób leczenia zaburzeń proliferacyjnych i innych stanów patologicznych, w których pośredniczy aktywność kinazowa BCR-AbI, c-Kit, DDR1, DDR2 lub PDGF-R

Info

Publication number: PL2501384T5
Authority: PL; Poland
Prior art keywords: ddr1; ddr2; bcr; abl; pdgf
Prior art date: 2009-11-17

Application number

PL10781781.9T

Other languages

English (en)

Other versions

PL2501384T3 (pl

Inventor

Neil Gallagher

Ophelia Yin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-17

Filing date

2010-11-17

Publication date

2024-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2501384(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-17 Application filed by Novartis Ag filed Critical Novartis Ag

2016-08-31 Publication of PL2501384T3 publication Critical patent/PL2501384T3/pl

2024-01-29 Publication of PL2501384T5 publication Critical patent/PL2501384T5/pl

Links

WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title 1
101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 title 1
108091000080 Phosphotransferase Proteins 0.000 title 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
230000001575 pathological effect Effects 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
230000002062 proliferating effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL10781781.9T 2009-11-17 2010-11-17 Sposób leczenia zaburzeń proliferacyjnych i innych stanów patologicznych, w których pośredniczy aktywność kinazowa BCR-AbI, c-Kit, DDR1, DDR2 lub PDGF-R PL2501384T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26181209P	2009-11-17	2009-11-17
PCT/US2010/056926 WO2011062927A1 (en)	2009-11-17	2010-11-17	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EP10781781.9A EP2501384B2 (en)	2009-11-17	2010-11-17	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity

Publications (2)

Publication Number	Publication Date
PL2501384T3 PL2501384T3 (pl)	2016-08-31
PL2501384T5 true PL2501384T5 (pl)	2024-01-29

Family

ID=43513643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10781781.9T PL2501384T5 (pl)	2009-11-17	2010-11-17	Sposób leczenia zaburzeń proliferacyjnych i innych stanów patologicznych, w których pośredniczy aktywność kinazowa BCR-AbI, c-Kit, DDR1, DDR2 lub PDGF-R

Country Status (37)

Country	Link
US (1)	US9061029B2 (pl)
EP (1)	EP2501384B2 (pl)
JP (2)	JP5829615B2 (pl)
KR (1)	KR101743315B1 (pl)
CN (1)	CN102612368B (pl)
AR (1)	AR079029A1 (pl)
AU (1)	AU2010322102B2 (pl)
BR (1)	BR112012011693A2 (pl)
CA (1)	CA2779490C (pl)
CL (1)	CL2012001270A1 (pl)
CO (1)	CO6551690A2 (pl)
DK (1)	DK2501384T4 (pl)
EC (1)	ECSP12011903A (pl)
ES (1)	ES2572128T5 (pl)
FI (1)	FI2501384T4 (pl)
GT (1)	GT201200150A (pl)
HR (1)	HRP20160472T4 (pl)
HU (1)	HUE027307T2 (pl)
IL (1)	IL219727A (pl)
JO (1)	JO3634B1 (pl)
MA (1)	MA33738B1 (pl)
ME (1)	ME02413B (pl)
MX (1)	MX2012005694A (pl)
MY (1)	MY169956A (pl)
NZ (1)	NZ599968A (pl)
PE (1)	PE20121476A1 (pl)
PH (1)	PH12012500965A1 (pl)
PL (1)	PL2501384T5 (pl)
RS (1)	RS54747B2 (pl)
RU (1)	RU2625835C2 (pl)
SG (1)	SG10201501169VA (pl)
SI (1)	SI2501384T2 (pl)
SM (1)	SMT201600143B (pl)
TN (1)	TN2012000206A1 (pl)
TW (1)	TWI498116B (pl)
WO (1)	WO2011062927A1 (pl)
ZA (1)	ZA201203328B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013068836A1 (en)	2011-11-07	2013-05-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
JP6177768B2 (ja)	2012-04-24	2017-08-09	中外製薬株式会社	ベンズアミド誘導体
HK1203943A1 (en)	2012-04-24	2015-11-06	中外制药株式会社	Quinazolinedione derivative
CA3134922A1 (en) *	2012-05-02	2013-11-07	Georgetown University	Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
PT2861579T (pt) *	2012-05-15	2018-04-27	Novartis Ag	Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
US20140080772A1 (en) *	2012-09-06	2014-03-20	The Board Of Regents Of The University Of Texas System	Treatments for melanoma
US9561245B2 (en)	2012-09-06	2017-02-07	The Board Of Regents Of The University Of Texas System	Combination treatments for melanoma
US9572828B2 (en)	2013-07-18	2017-02-21	The Board Of Regents Of The University Of Texas System	Treatment for melanoma
AU2014338070A1 (en)	2013-10-23	2016-05-05	Chugai Seiyaku Kabushiki Kaisha	Quinazolinone and isoquinolinone derivative
TW201718474A (zh) *	2015-08-31	2017-06-01	東麗股份有限公司	尿素衍生物及其用途
CN108103186B (zh) *	2018-02-28	2021-07-02	固安博健生物技术有限公司	诊断类风湿性关节炎和骨关节炎的分子标志物
TWI770624B (zh)	2018-06-15	2022-07-11	漢達生技醫藥股份有限公司	尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
KR102902341B1 (ko)	2018-11-20	2025-12-18	조지타운 유니버시티	신경 변성, 심근 변성 및 리소좀 축적 장애를 치료하기 위한 조성물 및 방법
WO2020144649A1 (en) *	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
IL295007A (en)	2020-01-31	2022-09-01	Nanocopoeia Llc	Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en)	2020-04-30	2021-11-04	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP2023543815A (ja)	2020-09-29	2023-10-18	シェンチェンファーマシンシーオー．，エルティーディー．	医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA04012845A (es)	2002-06-28	2005-02-24	Nippon Shinyaku Co Ltd	Derivado de amida.
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
AU2003257963B2 (en)	2002-08-01	2009-08-13	Board Of Trustees Of The University Of Arkansas	Improved treatment of cancer with glutamine
PT1879585E (pt)	2005-05-02	2013-07-23	Novartis Ag	Utilização de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistémica
SA06270147B1 (ar)	2005-06-09	2009-12-22	نوفارتيس ايه جي	عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es)	2005-07-20	2007-03-19		Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es)	2005-07-20	2007-04-02		Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en)	2006-09-27	2008-05-21	Novartis AG	Pharmaceutical compositions comprising nilotinib or its salt
KR100925559B1 (ko)	2007-10-26	2009-11-05	한국과학기술연구원	악티노마이신 ｄ를 유효성분으로 하는 ｄｄｒ과 콜라겐결합 저해제

2010
- 2010-11-14 JO JOP/2010/0396A patent/JO3634B1/ar active
- 2010-11-15 AR ARP100104212A patent/AR079029A1/es not_active Application Discontinuation
- 2010-11-16 TW TW099139425A patent/TWI498116B/zh active
- 2010-11-17 RS RS20160303A patent/RS54747B2/sr unknown
- 2010-11-17 RU RU2012124811A patent/RU2625835C2/ru active
- 2010-11-17 EP EP10781781.9A patent/EP2501384B2/en active Active
- 2010-11-17 SI SI201031172T patent/SI2501384T2/sl unknown
- 2010-11-17 ES ES10781781T patent/ES2572128T5/es active Active
- 2010-11-17 HU HUE10781781A patent/HUE027307T2/hu unknown
- 2010-11-17 JP JP2012539982A patent/JP5829615B2/ja active Active
- 2010-11-17 HR HRP20160472TT patent/HRP20160472T4/hr unknown
- 2010-11-17 FI FIEP10781781.9T patent/FI2501384T4/fi active
- 2010-11-17 ME MEP-2016-89A patent/ME02413B/me unknown
- 2010-11-17 DK DK10781781.9T patent/DK2501384T4/da active
- 2010-11-17 BR BR112012011693A patent/BR112012011693A2/pt not_active Application Discontinuation
- 2010-11-17 US US13/509,626 patent/US9061029B2/en active Active
- 2010-11-17 PH PH1/2012/500965A patent/PH12012500965A1/en unknown
- 2010-11-17 CN CN201080051819.0A patent/CN102612368B/zh not_active Ceased
- 2010-11-17 WO PCT/US2010/056926 patent/WO2011062927A1/en not_active Ceased
- 2010-11-17 NZ NZ599968A patent/NZ599968A/en not_active IP Right Cessation
- 2010-11-17 MY MYPI2012001993A patent/MY169956A/en unknown
- 2010-11-17 PE PE2012000667A patent/PE20121476A1/es not_active Application Discontinuation
- 2010-11-17 MX MX2012005694A patent/MX2012005694A/es active IP Right Grant
- 2010-11-17 SG SG10201501169VA patent/SG10201501169VA/en unknown
- 2010-11-17 CA CA2779490A patent/CA2779490C/en active Active
- 2010-11-17 PL PL10781781.9T patent/PL2501384T5/pl unknown
- 2010-11-17 AU AU2010322102A patent/AU2010322102B2/en active Active
- 2010-11-17 KR KR1020127012603A patent/KR101743315B1/ko active Active
2012
- 2012-05-07 TN TNP2012000206A patent/TN2012000206A1/en unknown
- 2012-05-08 ZA ZA2012/03328A patent/ZA201203328B/en unknown
- 2012-05-10 IL IL219727A patent/IL219727A/en active IP Right Grant
- 2012-05-11 MA MA34855A patent/MA33738B1/fr unknown
- 2012-05-16 CL CL2012001270A patent/CL2012001270A1/es unknown
- 2012-05-16 EC ECSP12011903 patent/ECSP12011903A/es unknown
- 2012-05-17 GT GT201200150A patent/GT201200150A/es unknown
- 2012-05-17 CO CO12081907A patent/CO6551690A2/es not_active Application Discontinuation
2015
- 2015-04-28 JP JP2015091857A patent/JP2015180636A/ja active Pending
2016
- 2016-05-23 SM SM201600143T patent/SMT201600143B/it unknown

Also Published As

Publication number	Publication date
MX2012005694A (es)	2012-06-13
TN2012000206A1 (en)	2013-12-12
RS54747B2 (sr)	2024-02-29
HK1169950A1 (zh)	2013-02-15
SI2501384T1 (sl)	2016-06-30
ECSP12011903A (es)	2012-09-28
IL219727A0 (en)	2012-07-31
AU2010322102A1 (en)	2012-05-24
WO2011062927A1 (en)	2011-05-26
DK2501384T3 (en)	2016-05-17
JP5829615B2 (ja)	2015-12-09
CA2779490A1 (en)	2011-05-26
JP2013511524A (ja)	2013-04-04
EP2501384B1 (en)	2016-02-17
HUE027307T2 (hu)	2016-10-28
AU2010322102B2 (en)	2014-08-28
ES2572128T5 (es)	2024-05-17
SMT201600143B (it)	2016-07-01
TWI498116B (zh)	2015-09-01
NZ599968A (en)	2014-09-26
US9061029B2 (en)	2015-06-23
RS54747B1 (sr)	2016-10-31
GT201200150A (es)	2014-08-11
CA2779490C (en)	2019-02-12
EP2501384A1 (en)	2012-09-26
KR101743315B1 (ko)	2017-06-15
ES2572128T3 (es)	2016-05-30
PE20121476A1 (es)	2012-11-14
BR112012011693A2 (pt)	2016-03-01
FI2501384T4 (fi)	2024-01-11
DK2501384T4 (da)	2024-01-02
CN102612368A (zh)	2012-07-25
PH12012500965A1 (en)	2016-10-05
PL2501384T3 (pl)	2016-08-31
KR20120102635A (ko)	2012-09-18
SG10201501169VA (en)	2015-04-29
IL219727A (en)	2016-07-31
SI2501384T2 (sl)	2024-02-29
RU2012124811A (ru)	2013-12-27
CO6551690A2 (es)	2012-10-31
ZA201203328B (en)	2013-02-27
JP2015180636A (ja)	2015-10-15
MY169956A (en)	2019-06-19
RU2625835C2 (ru)	2017-07-19
AR079029A1 (es)	2011-12-21
TW201141481A (en)	2011-12-01
JO3634B1 (ar)	2020-08-27
CN102612368B (zh)	2014-03-05
HRP20160472T1 (hr)	2016-06-03
EP2501384B2 (en)	2023-11-01
MA33738B1 (fr)	2012-11-01
HRP20160472T4 (hr)	2024-02-02
ME02413B (me)	2016-09-20
US20120289528A1 (en)	2012-11-15
CL2012001270A1 (es)	2012-10-12

Publication	Publication Date	Title
IL219727A0 (en)	2012-07-31	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2, or pdgf-r kinase activity
IL219109A0 (en)	2012-06-28	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
IL216140A0 (en)	2012-01-31	Egfr inhibitors and methods of treating disorders
WO2011090738A3 (en)	2011-11-24	Type ii raf kinase inhibitors
PH12012500712A1 (en)	2017-07-26	Inhibitors of bruton`s tyrosine kinase
IL226401A0 (en)	2013-07-31	Methods for treating disorders related to @fgfBA
AP2011005824A0 (en)	2011-08-31	Methods for treating acute myocardial infarctions and associated disorders.
ZA201405478B (en)	2016-06-29	Method and composition for enzymatic treatment of fiber for papermaking, and paper products made therewith
EP4219516A3 (en)	2024-01-10	Chiral control
EP3611254C0 (en)	2023-07-05	MICROORGANISMS AND METHODS FOR HEXAMETHYLENEDIAMINE BIOSYNTHESIS
EP3715457A3 (en)	2020-12-16	Modulation of prekallikrein (pkk) expression
WO2012135641A3 (en)	2012-12-27	Aurora kinase inhibitors and methods of making and using thereof
IL230704A0 (en)	2014-03-31	Double-stranded oligonucleotides for the treatment of hearing and balance disorders
WO2011085351A9 (en)	2011-12-22	Method of treating kcnq related disorders
WO2010077266A9 (en)	2010-09-30	Method of dynamic binary temperature therapy
IL215584A0 (en)	2011-12-29	Methods for preventing and/or treating degenerative disorders of the central nervous system
WO2012126542A3 (en)	2013-05-16	Biomarkers and methods for the prognosis of glioblastoma
GB2455585B (en)	2010-07-28	Capsicum seeds for the treatment of eczema and dermatitis
ZA201200124B (en)	2013-03-27	Method of treating age related disorders
WO2012125447A3 (en)	2012-12-06	Piperazinedione compounds
EP2303284A4 (en)	2013-04-24	METHOD FOR TREATING BIPOLAR DISORDER
HK1168048A (en)	2012-12-21	Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EP2528612A4 (en)	2013-07-17	METHODS OF TREATING GLUCOSE METABOLISM DISORDERS
EP2528614A4 (en)	2013-09-04	METHODS OF TREATING GLUCOSE METABOLISM DISORDERS
EP2523730A4 (en)	2013-10-23	METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES